Light Science Technologies (AIM: LST) shares recover as Injectaclad starts converting pipeline into revenue

Light Science Technologies Holdings plc (AIM: LST) has secured approximately £0.8 million of additional passive fire-protection business since its June trading update, giving investors fresh evidence that the company’s acquisition-led move into UK building remediation is beginning to generate meaningful revenue. The work combines further orders and invoiced sales of the Injectaclad cavity fire-barrier system through third-party installers with two additional contracts for the company’s own installation operation in Birmingham and Leicester.

The financial scale is more material than the headline number may initially suggest. Light Science Technologies generated only £3.73 million of group revenue during the six months ended May 31, meaning the latest £0.8 million of secured PFP business alone is equivalent to roughly 21% of first-half revenue. The shares closed around 1.90p on September 11, compared with approximately 1.45p immediately after the August interim results, although they remain a highly volatile microcap with a wide quoted spread.

Why does £0.8 million of new PFP business matter so much for Light Science Technologies?

The latest award is incremental to business disclosed in Light Science Technologies’ June update rather than a repackaging of earlier orders. It includes both product supply through the installer network and direct installation work, which is strategically important because management is trying to monetise Injectaclad through two complementary channels rather than depending entirely on its own labour capacity.

The Leicester installation has also received approval from the Building Safety Regulator, while the company said its PFP division is now supplying or undertaking work across high-rise residential buildings, hotels, schools and social housing. That broadens the addressable opportunity beyond any single building category.

For investors, commercial conversion is especially important because the group’s August interim numbers still reflected the disruption associated with its transformation. Revenue fell from £5.06 million to £3.73 million in the first half, while gross margin declined to 30.5% from 36.3%. Management said H1 had been a consolidation period following a £6.6 million gross fundraising and three strategic acquisitions.

Is Light Science Technologies moving past the weak first-half financial comparison?

The interim period was not flattering when viewed purely through historical revenue and margin comparisons, but it was also not representative of the enlarged business for the full six months. Injectaclad was acquired only on April 14, so the PFP platform made a limited contribution to H1 while acquisition costs, integration and external project delays affected reported performance.

That makes H2 disproportionately important. Management entered the second half with a more complete operating platform and has already pointed to stronger contract conversion. The September £0.8 million announcement is useful because it demonstrates that the improvement is not limited to an internal sales pipeline; signed and invoiced business is beginning to emerge.

Investors should still distinguish orders from recognised profit. Building-remediation projects require labour, materials and working capital, while contract timing can change. The next set of accounts needs to demonstrate not only higher revenue but also that Injectaclad can lift group gross margins rather than merely increasing turnover.

What does the LST share-price recovery tell investors after the August results?

Light Science Technologies closed around 1.45p on August 13, the day of the interim announcement, after falling approximately 9%. The shares subsequently recovered, reaching approximately 1.88p following the September 9 PFP announcement and closing around 1.90p on September 11.

That puts the post-interim recovery at roughly 30%, but context is essential. LST has traded across an exceptionally broad 52-week range and remains a sub-£20 million company, so relatively modest buying and selling can move the price sharply. The quoted bid-offer spread around September 11 was approximately 1.8p to 2.0p, or more than 11%, reinforcing the need to avoid treating every percentage movement as fundamental price discovery.

The more useful observation is therefore directional rather than precise. Investors initially reacted negatively to weak H1 numbers, but subsequent commercial announcements have rebuilt some confidence that the enlarged PFP operation can produce a much stronger second half.

What must Light Science Technologies prove before the rerating becomes durable?

The first requirement is revenue conversion. The company needs the growing PFP pipeline, installer orders and direct projects to translate into recognised sales within management’s expected timetable. The second requirement is margin improvement because the financial benefit of expanding into fire protection will ultimately be judged by contribution profit and cash generation rather than contract headlines.

Balance-sheet discipline is equally important following the acquisition programme. Light Science Technologies reported cash and undrawn facilities of £2.72 million at May 31 and subsequently indicated approximately £2.93 million at July 31, providing some liquidity but not enough to make working-capital management irrelevant for a rapidly expanding microcap.

The September announcement nevertheless changes the debate. The investment case is moving from whether the Injectaclad acquisition can attract demand toward whether the company can execute enough of that demand profitably. For LST shareholders, the second question is harder, but it is also substantially more valuable if management can answer it.